Alex Rolland and his team at Cancer Treatment Options and Management Inc. focus on advancing oncology research to enhance cancer diagnostics and treatment effectiveness. Their collaboration with Norgen Biotek has yielded significant advancements in liquid biopsy technology, particularly in extracting circulating tumor DNA (ct-DNA) and exosomal RNA from patient blood samples. By utilizing Norgen's innovative extraction kits, they achieved high yields of cancer-specific ct-DNA fragments, crucial for monitoring treatment responses and disease progression. Their approach includes custom probes to monitor treatment responses and detect mutations, crucial for guiding personalized therapies and improving patient outcomes worldwide.